Table 1.
Demographic data among different age groups with SARS-CoV-2 Omicron variant infection in the study.
| Total (N = 812) | Children (N = 246) | Adult (N = 265) | Elderly (N = 301) | |
|---|---|---|---|---|
| Sex (female ratio) | 389 (47.9%) | 107 (43.5%) | 136 (51.3%) | 146 (48.5%) |
| Age | 45.3 (9.4–74.5) | 2.9 (0.6–7.1) | 41.3 (32.5–53.6) | 80.0 (72.6–87.0) |
| Previous SARS-CoV-2 infection history | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Comorbidities | ||||
| Diabetes mellitus | 127 (15.6%) | 0 (0%) | 33 (12.5%) | 94 (31.2%) |
| Hypertension | 241 (29.7%) | 3 (1.2%) | 54 (20.4) | 184 (61.1%) |
| Hyperlipidemia | 101 (12.4%) | 1 (0.4%) | 32 (12.1%) | 68 (22.6%) |
| Cardiovascular disease | 166 (20.4%) | 14 (5.7%) | 25 (9.4%) | 127 (42.2%) |
| Chronic kidney disease | 90 (11.1%) | 1 (0.4%) | 30 (11.3%) | 59 (19.6%) |
| Cirrhosis or hepatic disease | 54 (6.7%) | 3 (1.2%) | 26 (9.8%) | 25 (8.3%) |
| Pulmonary disease | 32 (3.9%) | 7 (2.8%) | 4 (1.5%) | 21 (7.0%) |
| Autoimmune disease | 31 (3.8%) | 1 (0.4%) | 19 (7.2%) | 11 (3.7%) |
| Malignancy | 159 (19.6%) | 5 (2.0%) | 52 (19.6%) | 102 (33.9%) |
| Obesity or overweight | 11 (1.4%) | 2 (0.8%) | 9 (3.4%) | 0 (0%) |
| Medication | ||||
| Corticosteroid | 154 (19.0%) | 13 (5.3%) | 42 (15.8%) | 99 (32.9%) |
| Immunosuppressants | 59 (7.3%) | 7 (2.8%) | 24 (9.1%) | 28 (9.3%) |
| Vaccination status | ||||
| Unvaccinated | 438 (53.9%) | 239 (97.2%) | 67 (25.3%) | 132 (43.9%) |
| 1 dose | 46 (5.7%) | 2 (0.8%) | 19 (7.2%) | 25 (8.3%) |
| 2 doses | 104 (12.8%) | 4 (1.6%) | 60 (22.6%) | 40 (13.3%) |
| ≥3 doses | 224 (27.5%) | 1 (0.4%) | 119 (44.9%) | 104 (34.6%) |
| Treatment | ||||
| Oxygen supplement | 214 (26.4%) | 19 (7.7%) | 43 (16.2%) | 152 (50.5%) |
| Ventilator support | 62 (7.6%) | 8 (3.3%) | 11 (4.2%) | 43 (14.3%) |
| Antiviral agents | ||||
| Remdesivir | 365 (45.0%) | 42 (17.1%) | 110 (41.5%) | 213 (70.8%) |
| Ritonavir/nirmatrelvir or molnupiravir | 151 (18.6%) | 4 (1.6%) | 65 (24.5%) | 82 (27.2%) |